ACE2, a therapeutic target of COVID-19, needs to be treated with caution.

IF 2.5 4区 医学 Q3 VIROLOGY
Xiang'e Liu
{"title":"ACE2, a therapeutic target of COVID-19, needs to be treated with caution.","authors":"Xiang'e Liu","doi":"10.1007/s00705-025-06327-0","DOIUrl":null,"url":null,"abstract":"<p><p>Angiotensin-converting enzyme 2 (ACE2) has garnered significant attention for its crucial role in infection by both SARS-CoV and SARS-CoV-2. Consequently, it has emerged as a potential therapeutic target for treatment of COVID-19. It is therefore important to understand the mechanisms and modes of action of current and future treatments involving ACE2. Three important strategies have been explored in previous studies: (1) interruption of the interaction between ACE2 and the coronavirus spike protein using compounds or monoclonal antibodies, (2) capturing the extracellular virus by employing soluble ACE2 as a decoy, and (3) reducing the expression or inhibiting the activity of ACE2 through genetic approaches or drug intervention. However, the third strategy of inhibiting ACE2 activity as a means of treating COVID-19 is potentially risky, and the wisdom of pursuing this approach is subject to debate. Here, the advisability of using anti-ACE2 treatment in the context of SARS-CoV and SARS-CoV-2 infections is challenged by reviewing the physiological function of ACE2 and the mechanism of viral entry, emphasizing the pathological impairment of ACE2 that occurs during SARS-CoV and SARS-CoV-2 infection and arguing that the potential hazards associated with ACE2 impairment should be given more attention. Because of the important concerns regarding the potential side effects of ACE2 inhibition, researchers are strongly urged to approach this issue with caution.</p>","PeriodicalId":8359,"journal":{"name":"Archives of Virology","volume":"170 7","pages":"143"},"PeriodicalIF":2.5000,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of Virology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00705-025-06327-0","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"VIROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Angiotensin-converting enzyme 2 (ACE2) has garnered significant attention for its crucial role in infection by both SARS-CoV and SARS-CoV-2. Consequently, it has emerged as a potential therapeutic target for treatment of COVID-19. It is therefore important to understand the mechanisms and modes of action of current and future treatments involving ACE2. Three important strategies have been explored in previous studies: (1) interruption of the interaction between ACE2 and the coronavirus spike protein using compounds or monoclonal antibodies, (2) capturing the extracellular virus by employing soluble ACE2 as a decoy, and (3) reducing the expression or inhibiting the activity of ACE2 through genetic approaches or drug intervention. However, the third strategy of inhibiting ACE2 activity as a means of treating COVID-19 is potentially risky, and the wisdom of pursuing this approach is subject to debate. Here, the advisability of using anti-ACE2 treatment in the context of SARS-CoV and SARS-CoV-2 infections is challenged by reviewing the physiological function of ACE2 and the mechanism of viral entry, emphasizing the pathological impairment of ACE2 that occurs during SARS-CoV and SARS-CoV-2 infection and arguing that the potential hazards associated with ACE2 impairment should be given more attention. Because of the important concerns regarding the potential side effects of ACE2 inhibition, researchers are strongly urged to approach this issue with caution.

ACE2是COVID-19的治疗靶点,需要谨慎对待。
血管紧张素转换酶2 (angiotensin converting enzyme, ACE2)因其在SARS-CoV和SARS-CoV-2感染中的关键作用而受到广泛关注。因此,它已成为治疗COVID-19的潜在治疗靶点。因此,了解目前和未来涉及ACE2的治疗的机制和作用模式是很重要的。在以往的研究中,研究人员探索了三种重要的策略:(1)利用化合物或单克隆抗体中断ACE2与冠状病毒刺突蛋白的相互作用;(2)利用可溶性ACE2作为诱饵捕获细胞外病毒;(3)通过遗传方法或药物干预降低ACE2的表达或抑制其活性。然而,抑制ACE2活性作为治疗COVID-19的一种手段的第三种策略存在潜在风险,采用这种方法是否明智尚存争议。本文通过回顾ACE2的生理功能和病毒进入机制,对在SARS-CoV和SARS-CoV-2感染背景下使用抗ACE2治疗的可行性提出质疑,强调在SARS-CoV和SARS-CoV-2感染期间ACE2发生病理损伤,并认为应更多地关注ACE2损伤相关的潜在危害。由于对ACE2抑制的潜在副作用的重要关注,强烈敦促研究人员谨慎处理这个问题。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Archives of Virology
Archives of Virology 医学-病毒学
CiteScore
5.10
自引率
7.40%
发文量
324
审稿时长
4.5 months
期刊介绍: Archives of Virology publishes original contributions from all branches of research on viruses, virus-like agents, and virus infections of humans, animals, plants, insects, and bacteria. Coverage spans a broad spectrum of topics, from descriptions of newly discovered viruses, to studies of virus structure, composition, and genetics, to studies of virus interactions with host cells, organisms and populations. Studies employ molecular biologic, molecular genetics, and current immunologic and epidemiologic approaches. Contents include studies on the molecular pathogenesis, pathophysiology, and genetics of virus infections in individual hosts, and studies on the molecular epidemiology of virus infections in populations. Also included are studies involving applied research such as diagnostic technology development, monoclonal antibody panel development, vaccine development, and antiviral drug development.Archives of Virology wishes to publish obituaries of recently deceased well-known virologists and leading figures in virology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信